Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Friday, March 29, 2024 · 699,672,739 Articles · 3+ Million Readers

European Biosimilar Market to Reach US$ 25,446 Million by 2027 | Industry CAGR of 22.8%

SHERIDAN, WY, UNITED STATES, November 30, 2022 /EINPresswire.com/ -- According to the latest report by IMARC Group, titled โ€œ๐๐ข๐จ๐ฌ๐ข๐ฆ๐ข๐ฅ๐š๐ซ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐ข๐ง ๐„๐ฎ๐ซ๐จ๐ฉ๐ž: ๐ˆ๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐“๐ซ๐ž๐ง๐๐ฌ, ๐’๐ก๐š๐ซ๐ž, ๐’๐ข๐ณ๐ž, ๐†๐ซ๐จ๐ฐ๐ญ๐ก, ๐Ž๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ฒ ๐š๐ง๐ ๐…๐จ๐ซ๐ž๐œ๐š๐ฌ๐ญ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ-๐Ÿ๐ŸŽ๐Ÿ๐Ÿ•.โ€™ the biosimilar market in Europe reached a value of US$ 6,735 Million in 2021.ย Looking forward, IMARC Group expects the market to reach ๐”๐’$ ๐Ÿ๐Ÿ“,๐Ÿ’๐Ÿ’๐Ÿ” ๐Œ๐ข๐ฅ๐ฅ๐ข๐จ๐ง by 2027, exhibiting at a CAGR of 22.8% during 2022-2027.

๐ˆ๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐Ž๐ฏ๐ž๐ซ๐ฏ๐ข๐ž๐ฐ:

Biosimilars, also called subsequent entry biologics (SEBs), refer to medical products that are similar to reference biologics in terms of their quality, efficacy, safety, etc. They are generally produced from living organisms, including yeast, animal or plant cells, bacteria, etc., and have a complex molecular structure. In addition to this, biosimilars are manufactured under the guidance of licensed facilities that are considered as an essential part of post-market surveillance. As such, they are extensively utilized in the production of therapeutic proteins, vaccines, monoclonal antibodies, etc.

๐๐จ๐ญ๐ž: ๐–๐ž ๐š๐ซ๐ž ๐ซ๐ž๐ ๐ฎ๐ฅ๐š๐ซ๐ฅ๐ฒ ๐ญ๐ซ๐š๐œ๐ค๐ข๐ง๐  ๐ญ๐ก๐ž ๐๐ข๐ซ๐ž๐œ๐ญ ๐ž๐Ÿ๐Ÿ๐ž๐œ๐ญ ๐จ๐Ÿ ๐‚๐Ž๐•๐ˆ๐ƒ-๐Ÿ๐Ÿ— ๐จ๐ง ๐ญ๐ก๐ž ๐ฆ๐š๐ซ๐ค๐ž๐ญ, ๐š๐ฅ๐จ๐ง๐  ๐ฐ๐ข๐ญ๐ก ๐ญ๐ก๐ž ๐ข๐ง๐๐ข๐ซ๐ž๐œ๐ญ ๐ข๐ง๐Ÿ๐ฅ๐ฎ๐ž๐ง๐œ๐ž ๐จ๐Ÿ ๐š๐ฌ๐ฌ๐จ๐œ๐ข๐š๐ญ๐ž๐ ๐ข๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ข๐ž๐ฌ. ๐“๐ก๐ž๐ฌ๐ž ๐จ๐›๐ฌ๐ž๐ซ๐ฏ๐š๐ญ๐ข๐จ๐ง๐ฌ ๐ฐ๐ข๐ฅ๐ฅ ๐›๐ž ๐ข๐ง๐ญ๐ž๐ ๐ซ๐š๐ญ๐ž๐ ๐ข๐ง๐ญ๐จ ๐ญ๐ก๐ž ๐ซ๐ž๐ฉ๐จ๐ซ๐ญ.

๐ƒ๐จ๐ฐ๐ง๐ฅ๐จ๐š๐ ๐š ๐Ÿ๐ซ๐ž๐ž ๐ฌ๐š๐ฆ๐ฉ๐ฅ๐ž ๐ซ๐ž๐ฉ๐จ๐ซ๐ญ ๐ญ๐จ ๐ ๐ž๐ญ ๐š ๐๐ž๐ญ๐š๐ข๐ฅ๐ž๐ ๐จ๐ฏ๐ž๐ซ๐ฏ๐ข๐ž๐ฐ ๐จ๐Ÿ ๐ญ๐ก๐ž ๐ซ๐ž๐ฉ๐จ๐ซ๐ญ: https://www.imarcgroup.com/europe-biosimilar-market/requestsample

๐Œ๐š๐ซ๐ค๐ž๐ญ ๐“๐ซ๐ž๐ง๐๐ฌ:

The growing investments in the field of medical science and biotechnology are primarily driving the Europe biosimilar market. Moreover, the expanding geriatric population and the increasing prevalence of autoimmune diseases, cancer, diabetes, etc., owing to the sedentary lifestyle patterns of individuals, are also positively influencing the regional market. Apart from this, the launch of numerous favorable policies by government bodies and third-party payers in Europe to upgrade the existing healthcare infrastructures and the patent expiration of various blockbuster biologics are acting as significant growth-inducing factors. Furthermore, the development of state-of-the-art technology for comparing the characteristics, including chemical identity, purity, bioactivity, etc., of the proposed biosimilars to their reference product is stimulating the market growth. Besides this, the inflating need for safe and affordable alternatives to originator biological therapies is projected to fuel the Europe biosimilar market in the coming years.

๐๐ข๐จ๐ฌ๐ข๐ฆ๐ข๐ฅ๐š๐ซ๐ฌ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐ข๐ง ๐„๐ฎ๐ซ๐จ๐ฉ๐ž ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ-๐Ÿ๐ŸŽ๐Ÿ๐Ÿ• ๐‚๐จ๐ฆ๐ฉ๐ž๐ญ๐ข๐ญ๐ข๐ฏ๐ž ๐€๐ง๐š๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐š๐ง๐ ๐’๐ž๐ ๐ฆ๐ž๐ง๐ญ๐š๐ญ๐ข๐จ๐ง:

๐Š๐ž๐ฒ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐’๐ž๐ ๐ฆ๐ž๐ง๐ญ๐š๐ญ๐ข๐จ๐ง:

๐’๐จ๐ฆ๐ž ๐จ๐Ÿ ๐ญ๐ก๐ž ๐ฅ๐ž๐š๐๐ข๐ง๐  ๐ฉ๐ฅ๐š๐ฒ๐ž๐ซ๐ฌ:

Novartis
Pfizer
Tevaย 
Celltrionย 
Samsung Bioepisย 
Amgen
Apotexย 
Ratiopharm
Mylan
Merck Sharp & Dohme
Eli Lilly
Accord Healthcare Ltd
Boehringer Ingelheim
Hexal Agย 
Stada Arzneimittel Ag

๐Œ๐š๐ซ๐ค๐ž๐ญ ๐๐ซ๐ž๐š๐ค๐ฎ๐ฉ ๐›๐ฒ ๐Œ๐จ๐ฅ๐ž๐œ๐ฎ๐ฅ๐ž

Infliximab
Insulin Glargine
Epoetin Alfa
Etanercept
Filgrastim
Somatropin
Rituximab
Follitropin Alfa
Adalimumab

๐Œ๐š๐ซ๐ค๐ž๐ญ ๐๐ซ๐ž๐š๐ค๐ฎ๐ฉ ๐›๐ฒ ๐ˆ๐ง๐๐ข๐œ๐š๐ญ๐ข๐จ๐ง

Auto-Immune Diseases
Blood Disorder
Diabetes
Oncology
Growth Deficiency
Female Infertility

๐Œ๐š๐ซ๐ค๐ž๐ญ ๐๐ซ๐ž๐š๐ค๐ฎ๐ฉ ๐›๐ฒ ๐Œ๐š๐ง๐ฎ๐Ÿ๐š๐œ๐ญ๐ฎ๐ซ๐ข๐ง๐  ๐“๐ฒ๐ฉ๐ž

In-house Manufacturing
Contract Manufacturing

๐—•๐—ฟ๐—ฒ๐—ฎ๐—ธ๐˜‚๐—ฝ ๐—ฏ๐˜† ๐—–๐—ผ๐˜‚๐—ป๐˜๐—ฟ๐˜†:

Italy
Germany
United Kingdom
France
Spain
Others

ย Ask Analyst for 10% free customized report: https://www.imarcgroup.com/europe-biosimilar-market

๐™‰๐™ค๐™ฉ๐™š: We are updating our reports, If you want the report with the latest primary and secondary data (๐Ÿ๐ŸŽ๐Ÿ๐Ÿ‘-๐Ÿ๐ŸŽ๐Ÿ๐Ÿ–) including industry trends, market size and Competitive landscape, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.

๐Š๐ž๐ฒ ๐ก๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ ๐จ๐Ÿ ๐ญ๐ก๐ž ๐ซ๐ž๐ฉ๐จ๐ซ๐ญ:

๐Œ๐š๐ซ๐ค๐ž๐ญ ๐๐ž๐ซ๐Ÿ๐จ๐ซ๐ฆ๐š๐ง๐œ๐ž (๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”-๐Ÿ๐ŸŽ๐Ÿ๐Ÿ)
๐Œ๐š๐ซ๐ค๐ž๐ญ ๐Ž๐ฎ๐ญ๐ฅ๐จ๐จ๐ค (๐Ÿ๐ŸŽ๐Ÿ๐Ÿ-๐Ÿ๐ŸŽ๐Ÿ๐Ÿ•)
Market Trends
Market Drivers and Success Factors
Impact of COVID-19
Value Chain Analysis
Comprehensive mapping of the competitive landscape

๐๐จ๐ญ๐ž: ๐ˆ๐Ÿ ๐ฒ๐จ๐ฎ ๐ง๐ž๐ž๐ ๐ฌ๐ฉ๐ž๐œ๐ข๐Ÿ๐ข๐œ ๐ข๐ง๐Ÿ๐จ๐ซ๐ฆ๐š๐ญ๐ข๐จ๐ง ๐ญ๐ก๐š๐ญ ๐ข๐ฌ ๐ง๐จ๐ญ ๐œ๐ฎ๐ซ๐ซ๐ž๐ง๐ญ๐ฅ๐ฒ ๐ฐ๐ข๐ญ๐ก๐ข๐ง ๐ญ๐ก๐ž ๐ฌ๐œ๐จ๐ฉ๐ž ๐จ๐Ÿ ๐ญ๐ก๐ž ๐ซ๐ž๐ฉ๐จ๐ซ๐ญ, ๐ฐ๐ž ๐ฐ๐ข๐ฅ๐ฅ ๐ฉ๐ซ๐จ๐ฏ๐ข๐๐ž ๐ข๐ญ ๐ญ๐จ ๐ฒ๐จ๐ฎ ๐š๐ฌ ๐š ๐ฉ๐š๐ซ๐ญ ๐จ๐Ÿ ๐ญ๐ก๐ž ๐œ๐ฎ๐ฌ๐ญ๐จ๐ฆ๐ข๐ณ๐š๐ญ๐ข๐จ๐ง.

๐€๐›๐จ๐ฎ๐ญ ๐”๐ฌ:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCโ€™s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companyโ€™s expertise.


Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Elena Anderson
IMARC Services Private Limited
+ 16317911145
email us here

Powered by EIN Presswire


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release